ISG 15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Interferon-alpha (IFN-α) has recently been recognized to harbor therapeutic potential in prevention and treatment of HCC. IFN-stimulated gene 15 (ISG15) is an ubiquitin-like molecule that is strongly upregulated by type I interferons as a primary response to diverse microbial and cellular stress stimuli. Several studies have shown that the overexpression of ISG15 is correlated with multiply tumor types. However, the role of ISG15 in hepatitis B virus (HBV)-related HCC remains undetermined. ISG15 expression was found to be obviously higher in HBV-related HCC tissues than that in non-tumor tissues. ISG15 is a novel prognostic marker for predicting 5-year overall survival of HBV-related HCC patients. Overexpression of ISG15 was associated with clinicopathological characteristics and poor patient outcomes. ISG15 may serve as a novel prognostic marker for HBV-related HCC. Therefore, ISG15 may represent a novel HCC marker with prognostic significance and may be helpful in selecting patients for and predicting response to the treatment of HBV-related HCC.

[1]  Hong Zhang,et al.  Interferon-stimulated Gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma , 2014, Oncotarget.

[2]  Xiaohong Wang,et al.  Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line , 2014, Proceedings of the National Academy of Sciences.

[3]  C. Denkert,et al.  Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma: Prognostic Impact and Link to NF-&kgr;B Pathway , 2014, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[4]  D. Lamm,et al.  Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. , 2014, Urologic oncology.

[5]  Md. Asaduzzaman Khan,et al.  ISG15 Inhibits IFN-α-Resistant Liver Cancer Cell Growth , 2013, BioMed research international.

[6]  Basavaraj S. Salagundi,et al.  Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[7]  C. Brancolini,et al.  IFNs, ISGylation and cancer: Cui prodest? , 2012, Cytokine & growth factor reviews.

[8]  P. Schemmer,et al.  Treatment of Hepatocellular Carcinoma: A Systematic Review , 2012, Liver Cancer.

[9]  R. Finn.  Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition , 2012, Liver Cancer.

[10]  Hideo Negishi,et al.  The IRF family of transcription factors , 2012, Oncoimmunology.

[11]  M. Ntwasa,et al.  Modification by Ubiquitin-Like Proteins: Significance in Apoptosis and Autophagy Pathways , 2012, International journal of molecular sciences.

[12]  M. Zhang,et al.  Cynoglossus semilaevis ISG15: A Secreted Cytokine-Like Protein That Stimulates Antiviral Immune Response in a LRGG Motif-Dependent Manner , 2012, PloS one.

[13]  O. Silvennoinen,et al.  JAK Kinases in Health and Disease: An Update , 2012, The open rheumatology journal.

[14]  S. M. Ismail,et al.  Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11. , 2012, Oral diseases.

[15]  A. Wongnoppavich,et al.  Up-regulation of interferon-stimulated gene15 and its conjugates by tumor necrosis factor-α via type I interferon-dependent and -independent pathways , 2012, Molecular and Cellular Biochemistry.

[16]  J. Siegfried,et al.  SULF2 Methylation is Prognostic for Lung Cancer Survival and Increases Sensitivity to Topoisomerase-I inhibitors via Induction of ISG15 , 2011, Oncogene.

[17]  Andreas C Hadjivasiliou.  ISG15 implicated in cytoskeleton disruption and promotion of breast cancer. , 2012, Expert review of proteomics.

[18]  M. Seavey,et al.  The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy , 2012, Cancer Immunology, Immunotherapy.

[19]  S. Fan,et al.  Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience , 2011, Annals of surgery.

[20]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[21]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[22]  X. Shen,et al.  Interferon‐α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus‐related hepatocellular carcinoma , 2010, Journal of surgical oncology.

[23]  R. Krug,et al.  Species Specificity of the NS1 Protein of Influenza B Virus , 2010, The Journal of Biological Chemistry.

[24]  P. Galle,et al.  IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. , 2009, Cancer research.

[25]  植村 志乃美,et al.  Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer : increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance , 2009 .

[26]  Peter A Fasching,et al.  The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer , 2008, Breast Cancer Research.

[27]  Bryan R. G. Williams,et al.  Interferon-inducible antiviral effectors , 2008, Nature Reviews Immunology.

[28]  S. Kantsevoy,et al.  Endoscopic ultrasound and fine needle aspiration for the diagnosis of hepatocellular carcinoma. , 2008, Minerva gastroenterologica e dietologica.

[29]  P. Pitha,et al.  Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. , 2007, Cytokine & growth factor reviews.

[30]  T. Ørntoft,et al.  Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer , 2006, British Journal of Cancer.

[31]  E. Borden,et al.  Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. , 2005, Biochemical and biophysical research communications.